BPC 157 restored disabled myotendinous junctions in rats — injuries that normally don't heal — producing full functional recovery, reversed muscle wasting, and complete defect elimination by 42 days.
Complete defect disappearance by day 42BPC 157 fully healed myotendinous junction injuries in rats that showed no spontaneous healing in controls, with reversed muscle atrophy and full functional recovery
What the researchers found
BPC 157 completely restored disabled myotendinous junctions (where muscle connects to tendon) in rats — an injury that does not heal spontaneously. Both intraperitoneal injection (10 µg/kg and 10 ng/kg) and oral administration produced full functional recovery, reversed progressive muscle atrophy, and eliminated the structural defect by day 28-42.
BPC 157 treatment counteracted oxidative stress, normalized NO levels, and modulated eNOS and COX-2 mRNA expression at the injury site. Microscopically, treated rats showed well-oriented recovered tissue with no inflammatory infiltrate by days 28-42, while control rats showed consistently poor outcomes with progressive deterioration.
Why it matters
Myotendinous junction injuries — where muscle meets tendon — are among the most difficult musculoskeletal injuries to treat because this transition zone has poor natural healing capacity. Current treatments often require surgery with unpredictable outcomes. If BPC 157's dramatic healing effects in rats could translate to humans, it could transform treatment of common injuries like hamstring avulsions, rotator cuff tears at the muscle-tendon junction, and quadriceps tendon injuries.
The numbers in context
10 µg/kg and 10 ng/kg doses · IP and oral routes both effective · assessment at 7, 14, 28, 42 days · complete defect disappearance · oral dose: 0.16 µg/mL or 0.16 ng/mL in drinking water
How the study worked
Researchers surgically dissected the quadriceps tendon from the quadriceps muscle in rats, creating a myotendinous junction defect. BPC 157 was administered either by intraperitoneal injection (immediately after surgery and daily until sacrifice) or orally in drinking water. Healing was assessed at 7, 14, 28, and 42 days using macroscopic examination, microscopic histology, biomechanical testing, functional assessment, and molecular markers (eNOS, COX-2 mRNA, oxidative stress, NO levels).
Who was studied
Rats with surgically created quadriceps myotendinous junction defects
What this study cannot tell us
This is an animal study in rats, and results cannot be directly extrapolated to humans. The study comes from the Sikiric lab in Zagreb, which has produced the majority of BPC 157 research — independent replication by other groups is needed. No human clinical trials of BPC 157 for musculotendinous injuries exist. The specific sample sizes per group are not stated in the abstract.
How to read the evidence
This is a well-controlled animal study with multiple outcome measures (macroscopic, microscopic, biomechanical, functional, and molecular). However, it's a rat study from the same lab group that produces nearly all BPC 157 research, and no human data exists for this application. Evidence is rated low due to the preclinical nature and need for independent replication.
When this study was published
Published in 2021, this is relatively recent BPC 157 research. As of the publication date, no human clinical trials had been conducted for BPC 157 in musculotendinous healing.
The bigger picture
BPC 157 continues to generate attention for its apparent ability to heal tissues that normally have poor regenerative capacity. This study extends its demonstrated effects from individual muscles, tendons, and ligaments to the critical junction between them — arguably the weakest link in the musculoskeletal chain. The myotendinous junction is the most common site of muscle strain injuries in sports medicine. Combined with prior BPC 157 research showing healing of gut, bone, nerve, and vascular injuries, the breadth of tissue repair claims is remarkable — and also the reason independent replication is so important.
Questions still open
- Will BPC 157's myotendinous junction healing effects replicate in human clinical trials?
- What is the mechanism by which BPC 157 promotes tissue regeneration at the muscle-tendon interface specifically?
- Could BPC 157 be used to prevent or treat the chronic muscle atrophy that follows tendon injuries in humans?
Common questions
What is a myotendinous junction and why is it hard to heal?
Can BPC 157 be used by humans for tendon or muscle injuries?
Read the original research
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.
Biomedicines, 9(11)
Citation
Japjec, Mladen; Horvat Pavlov, Katarina; Petrovic, Andreja; Staresinic, Mario; Sebecic, Bozidar; Buljan, Matko; Vranes, Hrvoje; Giljanovic, Ana; Drmic, Domagoj; Japjec, Miroslav; Prtoric, Andreja; Lovric, Eva; Batelja Vuletic, Lovorka; Dobric, Ivan; Boban Blagaic, Alenka; Skrtic, Anita; Seiwerth, Sven; Predrag, Sikiric. (2021). Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.. Biomedicines, 9(11). https://doi.org/10.3390/biomedicines9111547